Delaware
|
1-11394
|
95-3863205
|
||
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
402 West County Road D, St. Paul, Minnesota
|
55112
|
|
(Address of principal executive offices)
|
(Zip Code)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
(c)
|
Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
MEDTOX Scientific, Inc. Press Release, dated April 12, 2012.
|
Exhibit No.
|
Description
|
|
99.1
|
MEDTOX Scientific, Inc. Press Release, dated April 12, 2012.
|
·
|
Total revenues increased 13.9% to $28.6 million
|
·
|
Gross profit increased 20.8% to $11.9 million
|
·
|
Operating income was $2.4 million, compared to $1.2 million, an increase of 91.4%
|
·
|
Net income was $1.5 million, compared to $0.8 million, an increase of 92.3%
|
·
|
Earnings per diluted share were $0.17, compared to $0.09 in the prior-year period
|
Three Months Ended
|
||||||
March 31, 2012
|
March 31, 2011
|
|||||
REVENUES:
|
||||||
Laboratory services:
|
||||||
Drugs-of-abuse testing services
|
$
|
10,578
|
$
|
9,640
|
||
Clinical & other laboratory services, net
|
9,185
|
7,336
|
||||
Clinical trial services
|
2,374
|
2,536
|
||||
Product sales
|
6,443
|
5,585
|
||||
28,580
|
25,097
|
|||||
COST OF REVENUES:
|
||||||
Cost of services
|
14,050
|
12,952
|
||||
Cost of sales
|
2,674
|
2,333
|
||||
16,724
|
15,285
|
|||||
GROSS PROFIT
|
11,856
|
9,812
|
||||
OPERATING EXPENSES:
|
||||||
Selling, general and administrative
|
8,807
|
7,985
|
||||
Research and development
|
689
|
594
|
||||
9,496
|
8,579
|
|||||
INCOME FROM OPERATIONS
|
2,360
|
1,233
|
||||
OTHER (EXPENSE) INCOME:
|
||||||
Interest expense
|
-
|
(24
|
)
|
|||
Other (expense) income
|
(4
|
)
|
16
|
|||
(4
|
)
|
(8
|
)
|
|||
INCOME BEFORE INCOME TAX EXPENSE
|
2,356
|
1,225
|
||||
INCOME TAX EXPENSE
|
(860
|
)
|
(447
|
)
|
||
NET INCOME
|
$
|
1,496
|
$
|
778
|
||
BASIC EARNINGS PER COMMON SHARE
|
$
|
0.17
|
$
|
0.09
|
||
DILUTED EARNINGS PER COMMON SHARE
|
$
|
0.17
|
$
|
0.09
|
||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
|
||||||
Basic
|
8,871,865
|
8,850,228
|
||||
Diluted
|
9,061,644
|
9,043,757
|
March 31,
2012
|
December 31,
2011
|
||||
ASSETS
|
|||||
Cash and cash equivalents
|
$ 7,048
|
$ 5,269
|
|||
Accounts receivable, net
|
18,855
|
17,209
|
|||
Inventories
|
4,728
|
4,568
|
|||
Other current assets
|
4,040
|
4,480
|
|||
Total current assets
|
34,671
|
31,526
|
|||
Building, equipment and improvements, net
|
27,166
|
28,105
|
|||
|
|||||
Other assets
|
17,160
|
17,223
|
|||
Total assets
|
$ 78,997
|
$ 76,854
|
|||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||
Current liabilities
|
$ 13,117
|
$ 12,725
|
|||
Long-term obligations
|
6,663
|
6,501
|
|||
Stockholders’ equity
|
59,217
|
57,628
|
|||
Total liabilities and stockholders’ equity
|
$ 78,997
|
$ 76,854
|
|||